Clonality studies in the analysis of adrenal medullary proliferations: Application principles and limitations

Endocrine Pathology

Volumn 9, Issue 4, 1998, Pages 301-316

  Diaz Cano, Salvador J ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Adrenal medullary hyperplasia; Clonality; Clone selection; Loss of heterozygosity; Multistep carcinogenesis; Pheochromocytoma; X chromosome inactivation

Indexed keywords

ADRENAL HYPERPLASIA; ARTICLE; CARCINOGENESIS; DIAGNOSTIC VALUE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; X CHROMOSOME INACTIVATION;

EID: 0032467118     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02739690     Document Type: Article

References (52)

1. Nowell PC. The clonal evolution of tumor cell populations. Science 194:23-28, 1976.
2. Fialkow PJ. Clonal origin of human tumors. Biochim Biophys Acta 458:283-321, 1976.
3. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: Implication for field cancerization. Cancer Res 56:2488-2492, 1996.
4. Jones PA, Droller MJ. Pathways of development and progression in bladder cancer: New correlations between clinical observations and molecular mechanisms. Semin Urol 11:177-192, 1993.
5. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med 319:525-532, 1988.
6. Hellman S. Darwin's clinical relevance. Cancer 79:2275-2281, 1997.
7. Diaz-Cano SJ, Wolfe HJ. PCR-based techniques for clonality analysis of neoplastic progression. Bases for its appropriate application in paraffin-embedded tissues. Histochem Cell Biol (in press).
8. Wainscoat JS, Fey MF. Assessment of clonality in human tumors: A review. Cancer Res 50: 1355-1360, 1990.
9. Gale RE, Wainscoat JS. Clonal analysis using X-linked DNA polymorphisms. Br J Haematol 85:2-8, 1993.
10. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgene receptor gene correlates with X chromosome inactivation. Am J Hum Genet 51:1229-1239, 1992.
11. Fialkow PJ. Primordial cell pool size and lineage relationships of five human cell types. Ann Hum Genet 37:39-48, 1973.
12. Kappler JW. The 5-methylcytosine content of DNA: tissue specificity. J Cell Physiol 78:33-36, 1971.
13. Latham KE. X chromosome imprinting and inactivation in the early mammalian embryo. TIG 12:134-137, 1996.
14. Page DL, DeLellis RA, Hough AJ Jr. Tumors of the adrenal. In: Atlas of tumor pathology, 2nd ser., fasci. 23. Washington DC: Armed Forces Institute of Pathology; 1986.
15. Lack EE. Tumors of the adrenal gland and extra-adrenal paraganglia. In: Atlas of tumor pathology, 3rd ser., fasci. 19. Washington DC: Armed Forces Institute of Pathology; 1997.
16. DeLellis RA, Wolfe HJ, Gagel RF, et al. Adrenal medullary hyperplasia. A morphometric analysis in patients with familial medullary thyroid carcinoma. Am J Pathol 83:177-190, 1976.
17. Carney JA, Sizemore GW, Sheps SG. Adrenal medullary disease in multiple endocrine neoplasia, type 1. Pheochromocytoma and its precursor. Am J Clin Pathol 66:279-290, 1976.
18. Neumann HP, Berger DP, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 329:1531-1538, 1993.
19. Williamson EA, Johnson SJ, Foster S, Kendall-Taylor P, Harris PE. G protein gene mutations in patients with multiple endocrinopathies. J Clin Endocrinol Metab 80: 1702-1705, 1995.
20. Linnoila RI, Keiser HR, Steinberg SM, Lack EE. Histopathology of benign versus malignant sympathoadrenal paragangliomas. Clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21:1168-1180, 1990.
21. Diaz-Cano SJ, de Miguel M, Galera-Davidson H, Wolfe HJ. Are locally invasive pheochromocytomas biologically distinct from benign chromaffin neoplasms? Pathol Int 46 (Suppl 1): 223, 1996.
22. Diaz-Cano SJ, Tashjian R, de Miguel M, et al. Distinctive clonal and histological patterns in locally invasive pheochromocytomas. Lab Invest 76:153A, 1997.
23. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA 90:10,914-10,921, 1993.
24. Knudson AG. Mutation and cancer: A personal odyssey. Adv Cancer Res 67:1-23, 1995.
25. Gutmann DH, Cole JL, Stone WJ, Ponder BA, Collins FS. Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I. Genes Chromosom Cancer 10:55-58, 1994.
26. Khosla S, Patel VM, Hay ID, Schaid DJ, Grant CS, van Heeren JA, et al. Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. J Clin Invest 87:1691-1699, 1991.
27. Moley JF, Brother MB, Fong CT, White PS, Baylin SB, Nelkin B, et al. Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes. Cancer Res 52:770-774, 1992.
28. Prowse AH, Webster AR, Richard S, Olschwang S, Resche F, Affara NA, et al. Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumors. Am J Hum Genet 60:765-771, 1997.
29. Shin E, Fujita S, Takami K, Kurahashi H, Kurita Y, Kobayashi T, et al. Deletion mapping of chromosome 1p and 22q in pheochromocytoma. Jpn J Cancer Res 84:402-408, 1993.
30. Vargas MP, Zhuang Z, Wang C, Vortmeyer A, Linehan WM, Merino MJ. Loss of heterozygosity of the short arm of chromosomes 1 and 3 in sporadic pheochromocytomas and extra-adrenal paraganglioma. Hum Pathol 28:411-415, 1997.
31. Yokogoshi Y, Yoshimoto K, Saito S. Loss of heterozygosity on chromosomes 1 and 11 in sporadic pheochromocytomas. Jpn J Cancer Res 81:632-638, 1990.
32. Boccia LM, Green JS, Joyce C, Eng C, Taylor SA, Mulligan LM. Mutation of RET codon 768 is associated with the FMTC phenotype. Clin Genet 51:81-85, 1997.
33. Baylin SB, Hsu SH, Gann DS, Smallridge RC, Wells SA Jr. Inherited medullary thyroid carcinoma: A final monoclonal mutation in one of multiple clones of susceptible cells. Science 199:429-431, 1978.
34. Baylin SB, Gann DS, Hsu SH. Clonal origin of inherited medullary thyroid carcinoma and pheochromocytoma. Science 193: 321-323, 1976.
35. Woodruff MF, Ansell JD, Forbes GM, Gordon JC, Burton DI, Micklem HS. Clonal interaction in rumours. Nature 299:822-824, 1982.
36. Knudson AG, Meadows AT. Regression of neuroblastoma IV-S: a genetic hypothesis. N Engl J Med 302:1254-1256, 1980.
37. Ferraris AM, Mangerini R, Gaetani GF, Romei C, Pinchera A, Pacini F. Polyclonal origin of medullary carcinoma of the thyroid in multiple endocrine neoplasia type 2. Hum Genet 99:202-205, 1997.
38. Chen LC, Kurisu W, Ljung BM, Goldman ES, Moore D II, Smith HS. Heterogeneity for allelic loss in human breast cancer. J Natl Cancer Inst 84:506-510, 1992.
39. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 274:2057-2059, 1996.
40. Wolman SR, Heppner GH. Genetic heterogeneity in breast cancer. J Natl Cancer Inst 84:469-470, 1992.
41. Sager R. Tumor suppressor genes: The puzzle and the promise. Science 246:1406-1412.
42. Weinberg RA. Tumor suppressor genes. Science 254:1138-1146.
43. Smith HS. Stochastic model for interpreting the data on loss of heterozygosity in breast cancer. J Nad Cancer Inst 82:793-794, 1990.
44. Mulcahy GM, Goggins M, Willis D, et al. Pathology and genetic testing. Workshop No. 6. Cancer 80:636-648, 1997.
45. Decker RA, Peacock ML. Update on the profile of multiple endocrine neoplasia type 2a RET mutations. Practical issues and implications for genetic testing. Cancer 80: 557-568, 1997.
46. Versteeg R. Aberrant methylation in cancer. Am J Hum Genet 60:751-754, 1997.
47. Laird PW, Jaenish R. DNA methylation and cancer. Hum Mol Genet 3:1487-1495, 1994.
48. Eng C. The RET proco-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 335:943-951, 1996.
49. Tischler AS, DeLellis RA, Nunnemacher G, Wolfe HJ. Acute stimulation of chromaffin cell proliferation in the adult rat adrenal medulla. Lab Invest 58:733-735, 1988.
50. Tischler AS, Ruzicka LA, Donahue SR, DeLellis RA. Pharmacological stimulation of chromaffin cell proliferation in the adult adrenal medulla. Arch Histol Cytol 52 (Suppl): 209-216, 1989.
51. Tischler AS, Ruzicka LA, Van Pelt CS, Sandusky GE. Catecholamine-synthesizing enzymes and chromogranin proteins in drug-induced proliferative lesions of the rat adrevnal medulla. Lab Invest 63:44-51, 1990.
52. Tischler AS, McClain RM, Childers H, Downing J. Neurogenic signals regulate chromaffin cell proliferation and mediate the mitogenic effect of reserpine in the adult rat adrenal medulla. Lab Invest 65:374-376, 1991.